{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:29:31Z","timestamp":1787225371988,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["ICMR 2020-5213"],"award-info":[{"award-number":["ICMR 2020-5213"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.prp.2022.153806","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T03:07:41Z","timestamp":1644635261000},"page":"153806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved"],"prefix":"10.1016","volume":"232","author":[{"given":"Sridhar","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshuman","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuzhat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2022.153806_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/1354750X.2012.717105","article-title":"Potential biomarkers in gallbladder cancer: present status and future directions","volume":"18","author":"Srivastava","year":"2013","journal-title":"Biomarkers"},{"key":"10.1016\/j.prp.2022.153806_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdu006","article-title":"A genetic model for gallbladder carcinogenesis and its dissemination","volume":"25","author":"Barreto","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1634\/theoncologist.2009-0302","article-title":"Current management of gallbladder carcinoma","volume":"15","author":"Zhu","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2022.153806_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02437-2","article-title":"Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience","volume":"18","author":"Wang","year":"2020","journal-title":"J. Trans. Med."},{"key":"10.1016\/j.prp.2022.153806_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.12998\/wjcc.v3.i3.231","article-title":"Gall bladder carcinoma: aggressive malignancy with protean loco-regional and distant spread","volume":"3","author":"Dwivedi","year":"2015","journal-title":"World J. Clin. cases"},{"key":"10.1016\/j.prp.2022.153806_bib6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1183\/16000617.00005814","article-title":"Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I\u2013IIIA","volume":"24","author":"Wallerek","year":"2015","journal-title":"Eur. Resp. Rev."},{"key":"10.1016\/j.prp.2022.153806_bib7","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.3748\/wjg.v23.i22.3978","article-title":"Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update","volume":"23","author":"Sharma","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.prp.2022.153806_bib8","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2009.27.4787","article-title":"Genetics of biliary tract cancers and emerging targeted therapies","volume":"28","author":"Hezel","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10555-016-9602-8","article-title":"Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design","volume":"35","author":"Sicklick","year":"2016","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.prp.2022.153806_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.prp.2022.153806_bib11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3892\/ol.2017.6224","article-title":"Genetic alterations in Japanese extrahepatic biliary tract cancer","volume":"14","author":"Noguchi","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2022.153806_bib12","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K\u2010ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2022.153806_bib13","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.18632\/oncotarget.1943","article-title":"Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups","volume":"5","author":"Simbolo","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2022.153806_bib14","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdu006","article-title":"A genetic model for gallbladder carcinogenesis and its dissemination","volume":"25","author":"Barreto","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.prp.2022.153806_bib16","article-title":"Identification of altered genes in gallbladder cancer as potential driver mutations for diagnostic and prognostic purposes: a computational approach.","volume":"25","author":"D\u2019Afonseca","year":"2020","journal-title":"Cancer Inform."},{"key":"10.1016\/j.prp.2022.153806_bib17","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/ijc.31916","article-title":"ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer","volume":"144","author":"Iyer","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2022.153806_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.18388\/abp.2003_3731","article-title":"TP53 and mutations in human cancer","volume":"50","author":"Szyma\u0144ska","year":"2003","journal-title":"Acta Biochim Pol."},{"key":"10.1016\/j.prp.2022.153806_bib19","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.7314\/APJCP.2014.15.13.5449","article-title":"High frequency of TP53 but not K-ras gene mutations in Bolivian patients with gallbladder cancer","volume":"15","author":"Asai","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.prp.2022.153806_bib20","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.prp.2022.153806_bib21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1665-2681(19)32065-4","article-title":"Miquel, TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma","volume":"4","author":"Moreno","year":"2005","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.prp.2022.153806_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1620\/tjem.172.283","article-title":"Mutation of the p53 gene in gallbladder cancer","volume":"172","author":"Takagi","year":"1994","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.prp.2022.153806_bib23","first-page":"117","article-title":"p53 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater","volume":"27","author":"Lee","year":"1995","journal-title":"Pathology"},{"key":"10.1016\/j.prp.2022.153806_bib24","first-page":"763","article-title":"Loss of heterozygosity in dysplasia and carcinoma of the gallbladder","volume":"12","author":"Chang","year":"1999","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2022.153806_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0046-8177(99)90295-2","article-title":"Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas","volume":"30","author":"Wistuba","year":"1999","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2022.153806_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35106009","article-title":"Assessing TP53 status in human tumors to evaluate clinical outcome","volume":"1","author":"Soussi","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2022.153806_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2022.153806_bib28","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.humpath.2013.11.001","article-title":"Molecular characterization of gallbladder cancer using somatic mutation profiling","volume":"45","author":"Javle","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2022.153806_bib29","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/ijc.31916","article-title":"ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer","volume":"144","author":"Iyer","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2022.153806_bib30","first-page":"1","article-title":"Overview of current targeted therapy in gallbladder cancer","volume":"5","author":"Song","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2022.153806_bib31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/annonc\/mdu175","article-title":"Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study","volume":"25","author":"Buzzoni","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH) 1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2022.153806_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-11-60","article-title":"Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma","volume":"11","author":"Deshpande","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2022.153806_bib34","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.prp.2022.153806_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","article-title":"Mutant PIK3CA promotes cell growth and invasion of human cancer cells","volume":"7","author":"Samuels","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.prp.2022.153806_bib36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","article-title":"Molecular profiling of biliary tract cancer: a target rich disease","volume":"7","author":"Jain","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-016-0432-2","article-title":"Genomic profiling of biliary tract cancers and implications for clinical practice","volume":"17","author":"Jain","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib38","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2022.153806_bib39","first-page":"42","article-title":"Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointest. Cancer Res."},{"key":"10.1016\/j.prp.2022.153806_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.suronc.2010.09.003","article-title":"Genetic aberrations in gallbladder cancer","volume":"21","author":"Maurya","year":"2012","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.humpath.2013.11.001","article-title":"Molecular characterization of gallbladder cancer using somatic mutation profiling","volume":"45","author":"Javle","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2022.153806_bib42","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2147\/OTT.S297643","article-title":"Promising molecular targets for the targeted therapy of biliary tract cancers: an overview","volume":"14","author":"Yang","year":"2021","journal-title":"Oncol. Targets Ther."},{"key":"10.1016\/j.prp.2022.153806_bib43","first-page":"1769","article-title":"Expression of Ezrin, HGF and C-met and its clinicopathological significance in the benign and malignant lesions of the gallbladder","volume":"59","author":"Yang","year":"2012","journal-title":"Hepato-Gastroenterol."},{"key":"10.1016\/j.prp.2022.153806_bib44","first-page":"1","article-title":"EGFR-an evolving cancer target","volume":"1","author":"Dakir","year":"2017","journal-title":"Cancer Biol. Ther. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib45","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-05-1692","article-title":"Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma","volume":"12","author":"Leone","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2022.153806_bib46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tranon.2014.12.003","article-title":"Molecular subgroup analysis of clinical outcomes in a phase 3 study of gemcitabine and oxaliplatin with or without erlotinib in advanced biliary tract cancer","volume":"8","author":"Kim","year":"2015","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.prp.2022.153806_bib48","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/modpathol.3800204","article-title":"Thuluvath, The V599E BRAF mutation is uncommon in biliary tract cancers","volume":"17","author":"Goldenberg","year":"2004","journal-title":"Mod. Pathol."},{"issue":"53","key":"10.1016\/j.prp.2022.153806_bib49","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3109\/0284186X.2014.895036","article-title":"The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis","volume":"2014","author":"Therkildsen","year":"2014","journal-title":"Acta Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib50","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.3892\/ol.2015.3600","article-title":"Determination of EGFR and KRAS mutational status in Greek non\u2011small\u2011cell lung cancer patients","volume":"10","author":"Papadopoulou","year":"2015","journal-title":"Oncol. Let."},{"key":"10.1016\/j.prp.2022.153806_bib51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-006-0075-x","article-title":"Diagnosis and surgical management of gallbladder cancer: a review","volume":"11","author":"Reid","year":"2007","journal-title":"J. Gastro Surg."},{"key":"10.1016\/j.prp.2022.153806_bib52","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/hep.22310","article-title":"Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment","volume":"48","author":"Blechacz","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.prp.2022.153806_bib53","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Bekaii-Saab","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib54","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/1758834011422557","article-title":"c-MET as a potential therapeutic target and biomarker in cancer","volume":"3","author":"Sierra","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib55","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.7150\/jca.17898","article-title":"The clinical impact of c-MET over-expression in advanced biliary tract cancer (BTC)","volume":"8","author":"Heo","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.prp.2022.153806_bib56","doi-asserted-by":"crossref","first-page":"46750","DOI":"10.18632\/oncotarget.8775","article-title":"The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets","volume":"7","author":"Chong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2022.153806_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-13-262","article-title":"Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4\u2013ALK-rearranged non\u2013small\u2013cell lung cancer harbored coexisting EGFR mutation","volume":"13","author":"Miyanaga","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2022.153806_bib58","article-title":"The landscape of MET mutations in Chinese biliary tract cancers","volume":"38","author":"Shifeng","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib59","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cels.2018.08.010","article-title":"A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-\u03b2 superfamily","volume":"7","author":"Korkut","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.prp.2022.153806_bib60","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijrobp.2013.06.2039","article-title":"Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma","volume":"87","author":"Herman","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.prp.2022.153806_bib61","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1172\/JCI27282","article-title":"Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice","volume":"116","author":"Xu","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.prp.2022.153806_bib62","doi-asserted-by":"crossref","unstructured":"K. Ohshiro, S. Zaidi, A. Korkut, J. Chen, S. Rao, S. Gu, W. Jogunoori, B. Mishra, R. Akbani, L. Mishra, A pan-cancer analysis reveals high frequency genetic alterations in mediators of signaling by the TGF-\u03b2 superfamily, In: Proceedings of the AACR Annual Meeting 2019. doi:10.1158\/1538-7445.AM2019-3382.","DOI":"10.1158\/1538-7445.AM2019-3382"},{"key":"10.1016\/j.prp.2022.153806_bib63","first-page":"3406","article-title":"\u03b2-catenin mutations in biliary tract cancers: a population-based study in China","volume":"61","author":"Rashid","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2022.153806_bib64","first-page":"19","article-title":"More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages","volume":"61","author":"Yanagisawa","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2022.153806_bib65","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.prp.2022.153806_bib66","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mds008","article-title":"Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer","volume":"23","author":"Jensen","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2022.153806_bib67","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.prp.2022.153806_bib68","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.3390\/jcm10143108","article-title":"Chemotherapy for Biliary Tract Cancer","volume":"10","author":"Sasaki","year":"2021","journal-title":"J Clin Med"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822000498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822000498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:49:54Z","timestamp":1759733394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033822000498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":68,"alternative-id":["S0344033822000498"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2022.153806","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2022.153806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"153806"}}